Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 6-K

Clearmind Medicine Inc.

CMNDNASDAQEQUITYCurrent

SEC Filing

Filed Sep 23, 2026Accepted Sep 23, 2026, 8:00 AM EDTCIK 1892500Accession 0001213900-26-102371
Share

Company context

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

Current securities

Historical securities (1)

Recent company filings

  1. 6-K filingSep 17, 2026
  2. 6-K filingSep 14, 2026
  3. 6-K filingSep 10, 2026
  4. 6-K filingSep 8, 2026
  5. 6-K filingSep 4, 2026

As-filed source

Primary evidence